Your session is about to expire
← Back to Search
Stem Cell Infusion for Kidney Transplant Tolerance
Study Summary
This trial will study whether patients with a kidney transplant from a HLA-identical living donor can stop taking immunosuppressive drugs without damaging the transplanted kidney, by receiving hematopoietic stem cells from the same donor.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowTimeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Trial Design
Find a Location
Logistics
Participation is compensated
You will be compensated for participating in this trial.
Who is running the clinical trial?
Media Library
- My donor is my identical twin.I do not have any unmanaged ongoing illnesses.I have received transplants for more than one organ.My current kidney transplant has not been rejected.I do not have active infections like hepatitis or HIV.I have positive donor-specific antibodies.I haven't had cancer in the last 5 years, except for certain types.My kidney disease is likely to come back.I haven't had major issues like new cancer, infections, or rejection after my transplant.I have recently used drugs that affect my immune system.I have no known allergies or adverse reactions to rATG or radiation.I am able to care for myself but may not be able to do active work.My body has rejected a kidney transplant that was a good match.I agree to join the study and can give my consent.I received a kidney transplant between 3 months and 5 years ago.My kidney function has worsened by more than 30% in the last 3 months.My liver tests are within the required range.I am 18 or older and have a kidney transplant from a matching living donor.My heart pumps well, with an ejection fraction of 40% or higher.My kidney function has been stable for at least 3 months.I am eligible for a stem cell transplant according to my hospital's rules.I have severe liver scarring due to hepatitis B or C.
- Group 1: Immune tolerance in HLA-identical kidney transplant recipient
- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
Have Conditioning and Stem cell infusion been officially recognized by the FDA?
"With limited evidence to support safety and efficacy, our experts at Power assigned a score of 1 when evaluating the risk associated with Conditioning and Stem Cell infusion."
Are there any opportunities for participants to join this experiment?
"This particular medical trial is no longer recruiting patients, as indicated by clinicaltrials.gov; it was initially posted on September 1st 2022 and its latest revision occurred on the last day of August. Fortunately, there are 603 other studies that are presently looking for participants to join their trials."
Share this study with friends
Copy Link
Messenger